A Study of Ormeloxifene in Treatment of Menorrhagia in Dysfunctional Uterine Bleeding in Reproductive age Group

Abstract

Introduction: Menorrhagia is abnormal vaginal bleeding from genital tract .^1,2,3 Average menstrual blood loss is between 30-40 ml per cycle. It affects 10-30% of women at some stage in their life. The dysfunctional uterine bleeding is largely unknown but occurs in both ovulatory and anovulatory menstrual cycles . The treatment of menorrhagia is a demanding task and various drugs like antifibrinolytics, non-steroidal anti-inflammatory drugs (NSAIDs), progesterones, combined estrogen and progesterones, danazol, gonadotrophin releasing hormone analogues and levonorgesterol-releasing intrauterine system have all been used with different results in the management of menorrhagia.

Aim and Objective: To evaluate the study of ormeloxifene in treatment of menorrhagia in dysfunctional uterine bleeding in reproductive age group.

Material and Methods: This was a Hospital based prospective randomize control study started from November 2020 to October 2021 at Department of Obstetrics and Gynecology, S.P.Medical College & AGH, Bikaner, Rajasthan, India. The study included Sample size of 40 Patients whose detailed history and clinical examination was done. As AUB is a diagnosis of exclusion investigation were done to rule out any other possible cause for abnormal uterine bleeding. These included complete blood cell count including hemoglobinlevel, thyroid stimulating hormone, coagulation profile, PAP smear, pelvic ultrasound to measure endometrial thickness and rule out any pelvic pathology and endometrial sampling.

Result: The study included Sample size of 40 Patients whose detailed history and clinical examination was done. 83.33% cases in pre-treatment group and 19.4% patients in post-treatment group showed dysmenorrhoea. Mean age of patients was 30.2±7.92 years and majority of cases belonged to 18-30 year. In present study, majority of patients belong to urban area and Majority of patients belong to Hindu religion.

Conclusion: It can be concluded that both ormeloxifene and OCPills  significantly reduce blood loss in patients of reproductive age group AUB evidenced by decrease of PBAC score, rise in hemoglobin levels and decrease in ET levels. However, ormeloxifene was found to be superior to OCPills in reducing the menstrual blood loss. Ormeloxifene was also tolerated better compared to OCPills with fewer side effects experienced by patients. Compliance with the drug, dosage schedule and effect on quality of life was also better with ormeloxifene compared to OCPills .So Ormeloxifene could be the drug of choice in patients of AUB in the reproductive age group.

Key words:  Ormeloxifene, Menorrhagia, Dysfunctional Uterine Bleeding.